Month: September 2026

Previously announced follow-on orders from an existing governmental intelligence customer reflect continued operational use of Maris-Tech’s edge video and AI technology in mission-critical, bandwidth-constrained environments

Rehovot, Israel, Sept. 14, 2026 (GLOBE NEWSWIRE) — Maris-Tech Ltd. (Nasdaq: MTEK, MTEKW) (“Maris-Tech” or the “Company”), a global provider of video and artificial intelligence (“AI”)-based edge computing technology, today provided an update highlighting a series of previously announced orders from an existing governmental customer operating in the intelligence gathering domain, including follow-on orders announced in June 2026 and an additional follow-on order announced in August 2026.

The June orders extended the ongoing deployment of Maris-Tech’s edge video and AI systems and reflected continued operational use in mission-critical environments. The August order continued a series of product deployments with the same customer, which is already operating Maris-Tech systems in the field for intelligence gathering applications, and followed earlier orders announced in March, April and June 2026.

Taken together, the orders reinforce the customer’s sustained use of the Company’s solutions for real-time video capture, processing and transmission directly at the point of collection, including in bandwidth-constrained conditions.

Israel Bar, Chief Executive Officer of Maris-Tech, said: “The repeat orders we have received from a customer already operating our systems in the field are the clearest signal we can ask for. An additional order from that same customer provides meaningful validation of both the technology and our ability to support its operational requirements. We believe these previously announced orders demonstrate how our solutions perform when they matter.”

Maris-Tech continues to support intelligence and defense-related applications with edge-based video and AI technologies designed for deployment in complex operational conditions.

About Maris-Tech Ltd.

Maris-Tech is a global leader in video and AI-based edge computing technology, pioneering intelligent video transmission solutions that conquer complex encoding-decoding challenges. The Company’s miniature, lightweight, and low-power products deliver high-performance capabilities, including raw data processing, seamless transfer, advanced image processing, and AI-driven analytics. Founded by Israeli technology sector veterans, Maris-Tech serves leading manufacturers worldwide in defense, aerospace, intelligence gathering, homeland security, and communication industries. We’re pushing the boundaries of video transmission and edge computing, driving innovation in mission-critical applications across commercial and defense sectors.

For more information, visit https://www.maris-tech.com/

Forward-Looking Statements Disclaimer

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the “safe harbor” created by those sections. Forward-looking statements, which are based on certain assumptions and describe the Company’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as “believe,” “expect”,” “may”, “should,” “could,” “seek,” “intend,” “plan,” “goal,” “estimate,” “anticipate” or other comparable terms. For example, the Company is using forward-looking statements when it discusses its belief regarding the significance of previously announced repeat orders from an existing governmental intelligence customer, including the extent to which such orders validate the Company’s technology and its ability to support the customer’s operational requirements, and the Company’s ability to continue to support intelligence and defense-related applications with its edge-based video and AI technologies. The Company’s actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause the Company’s actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: its ability to successfully market its products and services, including in the United States; the acceptance of its products and services by customers; its continued ability to pay operating costs and ability to meet demand for its products and services; the amount and nature of competition from other security and telecom products and services; the effects of changes in the cybersecurity and telecom markets; its ability to successfully develop new products and services; its success establishing and maintaining collaborative, strategic alliance agreements, licensing and supplier arrangements; its ability to comply with applicable regulations; and the other risks and uncertainties described in the Annual Report on Form 20-F for the year ended December 31, 2025, filed with the SEC on May 15, 2026, and its other filings with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor Relations:

Nir Bussy, CFO
Tel: +972-72-2424022
Nir@maris-tech.com

DENVER, Sept. 14, 2026 (GLOBE NEWSWIRE) — (247marketnews.com) — NeOnc Technologies Holdings (NASDAQ: NTHI) is sending investors a signal that is impossible to ignore.

The company’s CEO, President and director, Amir F. Heshmatpour, just bought another 37,000 shares of NTHI at $3.6654 apiece, putting approximately $136,000 of his own money behind the stock and the timing is what makes this purchase particularly intriguing.

NeOnc had just announced a $15 million registered direct offering at $4.20 per share, meaning Heshmatpour’s latest purchase occurred at a substantial discount to the financing price.

That is not the kind of insider transaction small-cap biotech traders casually dismiss.

Heshmatpour has been buying NTHI repeatedly and he isn’t the only insider who has been putting money behind the company. In August, Heshmatpour bought additional shares, while founder and Chief Scientific Officer Thomas C. Chen also made substantial purchases.

The Clinical Catalyst

NeOnc reported topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma. The company reported a 48.9% six-month progression-free survival rate, versus a pre-specified 20% benchmark.

Even more eye-catching: the company reported a 26.09-month median overall survival.

Five of 24 patients remained on treatment at the data cutoff, including one patient with progression-free survival approaching 19 months and another with an ongoing partial response. For a company operating in one of oncology’s toughest areas, those numbers naturally attracted attention, but the real story may be what comes next.

NeOnc says it plans to request a Type B meeting with the FDA to discuss the potential registrational path for NEO100. CEO Heshmatpour said the company’s priority is “to engage with the FDA and align on the most efficient path toward a registrational study,” which is a major potential inflection point.

If FDA discussions produce a viable path forward, NEO100 could move from an intriguing clinical-stage asset toward a potentially registrational development program, which makes the insider buying even more interesting, because Heshmatpour is buying after clinical data have been released and while the company is pursuing regulatory discussions.

The Blood-Brain Barrier

There is another piece investors cannot ignore: the blood-brain barrier.

Brain tumors are notoriously difficult to treat because getting drugs into the brain is itself a major challenge. NeOnc’s NEO100 program uses intranasal delivery designed to facilitate delivery to the brain through olfactory and trigeminal pathways.

If that approach can translate into meaningful clinical benefit, the opportunity could extend well beyond one small study.

NEO100’s Phase 2a study was small, open-label and single-arm. Larger studies are needed. FDA discussions do not guarantee a registrational pathway, or approval.

The company has simultaneously been advancing NEO100 and NEO212, raising capital and moving toward additional clinical and regulatory milestones.

For investors hunting for small-cap biotech names before major catalysts, that’s the part of the story that deserves attention, and if NEO100’s clinical signal ultimately translates into a successful registrational program, today’s insider buying could look considerably more significant in hindsight.

About 24/7 Market News

In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.

This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.

Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.

CONTACT:
24/7 Market News
Editor@247mnn.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.

President and CEO Sanjeev Luther to present on Wednesday, September 16, 2026, at 12:00 p.m. ET

Management available for one-on-one meetings with investors during the conference

CAMBRIDGE, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — Ernexa Therapeutics (Nasdaq: ERNA), an industry innovator developing novel cell therapies for the treatment of advanced cancers, today announced that Sanjeev Luther, President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference, being held September 14–16, 2026, in New York City.

During the presentation, Mr. Luther will provide an overview of Ernexa’s focused oncology strategy and recent progress with ERNA-101, the Company’s lead oncology cell therapy candidate. The presentation will highlight Ernexa’s differentiated, off-the-shelf-induced mesenchymal stem cell, or iMSC, platform, the growing body of preclinical evidence supporting ERNA-101 and the Company’s planned transition toward clinical development.

Presentation Details for Conference Attendees:

Conference: H.C. Wainwright 28th Annual Global Investment Conference
Presenter: Sanjeev Luther, President & CEO
Date: Wednesday, September 16, 2026
Time: 12:00 p.m. ET
Location: Kennedy I, 4th Floor

In addition to the presentation, Ernexa management will be available for one-on-one meetings with qualified investors during the conference. Investors interested in meeting with Ernexa management are encouraged to contact their H.C. Wainwright representative to request a meeting.

For more information about the conference, please visit the conference website.

About Ernexa Therapeutics

Ernexa Therapeutics (NASDAQ: ERNA) is developing innovative cell therapies for the treatment of advanced cancers. Ernexa’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Ernexa’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting.

ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system’s response to recognize and attack cancer cells. The company’s initial focus is to develop ERNA-101 for the treatment of ovarian cancer, with the potential to address multiple difficult-to-treat solid tumors.

For more information, visit www.ernexatx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “design,” “intend,” “expect,” “could,” “plan,” “potential,” “predict,” “seek,” “should,” “would,” “contemplate,” “project,” “target,” “objective,” or the negative version of these words and similar expressions. Forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Ernexa’s actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Ernexa’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Ernexa’s risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Ernexa does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date here of, except as required by applicable law.

Media Contact
Sharon Golubchik
RAYNZ
sharon@raynzhealth.com

Investor Contact
Jenene Thomas
JTC Team, LLC
(908) 824-0775
ERNA@jtcir.com

Sanofi and Cheplapharm to create new strategic partnership in mature medicines

Paris, September 14, 2026. Sanofi and Cheplapharm, a European leader in well-established medicines, today announced their intention to create a strategic partnership under which Cheplapharm would take over from Sanofi a selection of 20 mature medicines and three manufacturing sites worldwide. In return, Sanofi will receive a 26.4% equity stake in Cheplapharm, building on a collaboration that started in 2014.
The partnership is based on a shared conviction: that innovative medicines and certain mature medicines have different needs and should benefit from operating models tailored to their specific manufacturing, regulatory and commercial requirements. Cheplapharm’s specialized expertise will ensure these medicines continue to meet patients’ needs throughout the next stage of their lifecycle.

“Our multi-year journey to simplify our mature portfolio has enabled us to focus on innovation while ensuring mature medicines continue to reach patients who need them. Cheplapharm has been a trusted partner for more than a decade and this transaction significantly builds on its prior acquisitions from Sanofi’s mature medicines portfolio. This new partnership, together with our equity stake in Cheplapharm, underscores our commitment to ensuring patients continue to benefit from today’s essential medicines while also pursuing tomorrow’s breakthroughs,” said Thomas Grenier, Executive Vice President, General Medicines, Sanofi.

“This partnership marks a major milestone for Cheplapharm. Through this project, we are incorporating products that complement our extensive portfolio, as well as the expertise and manufacturing capabilities required to produce a flagship product, Lovenox®/Clexane®. This represents a long-term pharmaceutical and industrial commitment: to invest in our sites and their expertise, to preserve rare skills, and to ensure the long-term availability of these treatments for patients.” “We are proud to pursue this ambition alongside Sanofi,” said Edeltraud Lafer and Sebastian Braun, both Co-CEOs of Cheplapharm. 

As part of the project, three manufacturing sites would be transferred to Cheplapharm: Csanyikvölgy in Hungary (c.400 employees), Jurong in Singapore (c.100 employees), and Ploërmel in France (c.65 employees). The teams would continue their activities with existing employment arrangements and collective agreements maintained. Sanofi and Cheplapharm will work closely together to ensure a smooth transition and continuity of supply in compliance with the highest manufacturing quality standards.

The commercial transfer of the medicine portfolio is planned to begin in the first quarter of 2027, followed by the transfer of the sites, subject to employee information and consultation procedures with employee representatives, regulatory approvals and customary closing conditions. The transaction is expected to be fully completed by the third quarter of 2027.

For Cheplapharm, this partnership represents an important step ensuring the continuity of its strategic growth. For Sanofi, it will enable the company to continue focusing its efforts on innovation, while supporting certain established medicines through the next stage of their lifecycle.

Financial considerations for Sanofi 
The proposed transaction is not expected to have any impact on Sanofi’s financial guidance for 2026. The medicines being divested from Sanofi include Lovenox/Clexane (enoxaparin)1. Additional financial details are expected to be provided at a later stage.

 [1] Excluding in the US.

 

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

About Cheplapharm 
Cheplapharm  is a European family-owned pharmaceutical company based in Germany, specializing in well-established originator medicines. Driven by a long-term vision of sustainable growth, the Group has invested more than €6.2 billion since its inception, acquired nearly 100 products since 2015, and holds 3,440 marketing authorizations across 160 countries. Cheplapharm is the market leader in France and a leading European player in this market segment.

Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Laura Romby | +33 6 74 16 74 29 |  laura.romby@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com
Victor Rouault | +1 617 356 4751 | victor.rouault@sanofi.com 
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com 

Investor Relations
Thomas Kudsk Larsen | + 44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com

Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

Press contact Cheplapharm
Sandra Ammara : +33 6 79 92 71 34 – communication@cheplapharm.fr 

Sanofi Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. 
Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,” “outlook,” “guidance,” or the negative of these, and similar expressions are intended to identify forward-looking statements. 
Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete capital markets or other transactions, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with developing standalone businesses and with intellectual property, as well as any related pending or future litigation and the ultimate outcome of such litigation; and other risks associated with  trends in exchange and interest rates, volatile economic, political and financial and market conditions, cost containment initiatives, and the impact that global crises may have. More specifically regarding the transaction described above, these risks and uncertainties include among other things the possibility that the transaction will not be completed, or if completed, will not be completed in the expected timeframe, an unexpected failure to satisfy the required closing conditions, or unexpected delays in meeting these requirements, the ability to obtain regulatory clearances, the possibility that the expected strategic benefits, synergies or opportunities from the transaction may not be realized, or may take longer to realize than expected. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. In light of these risks, uncertainties and assumptions, you should not place undue reliance on any forward-looking statements contained herein. 
All trademarks mentioned in this press release are the property of the Sanofi group.

 

Attachment

• Press Release

Founder and CEO outlines NextNRG’s vision, technology platform and path forward

MIAMI, FL, Sept. 14, 2026 (GLOBE NEWSWIRE) — NextNRG, Inc. (Nasdaq: NXXT) (“NextNRG” or the “Company”), a pioneer in AI-driven energy innovation transforming how energy is produced, managed, and delivered, today announced that Founder and Chief Executive Officer, Michael D. Farkas, has issued the following letter to the Company’s shareholders outlining his perspective on NextNRG’s business, technology platform and opportunities ahead:

Letter to Our Shareholders

I have spent the better part of my career building companies in industries that were changing before the market fully understood where they were going. I founded NextNRG with the same conviction: that the way businesses produce, store and use energy is changing, and that the companies willing to build for that future will have an opportunity to create lasting value.

I still believe that as strongly as I did when we started. I want to take this opportunity to speak directly to you about where we are headed.

The market will always put a price on a company. Our job is to build the company that ultimately determines what that price is worth. That is where my focus is.

NextNRG is building an integrated energy platform around a simple idea: businesses need more agency over how they generate, store and use energy. Our opportunity is to bring together the technology, infrastructure and operating capabilities to help them do that.

We have spent years building the foundation for that opportunity. We have developed technology, established an operating business, secured agreements and developed a pipeline of projects that we believe can become sources of future revenue, including, in the healthcare sector alone, multiple facility projects at different stages of development.

Projects like these take real time to move from an agreement to operational, and that timeline is not always visible from the outside. But the work behind the scenes is real, and it is where our team remains focused.

And we are beginning to see opportunities to extend the value of capabilities we have already built beyond their original purpose.

That is how I think about NextNRG’s future. We are building on what we have already created while continuing to look for opportunities to expand the value of our technology and infrastructure. The goal is not to chase every opportunity. It is to build businesses around capabilities we believe have real value, and to execute against opportunities we believe make sense for NextNRG.

There is more in the pipeline, and we will announce each project when it is signed, not before. Our focus is on turning the opportunities in front of us into operating projects and new sources of revenue.

I founded NextNRG. I am deeply invested in its future, and I have not sold a share of my position.

Our job now is to execute and be straightforward with our shareholders about how it is going.

I believe in what we are building, and I believe the opportunity ahead of NextNRG is significant.

Michael D. Farkas

Founder and Chief Executive Officer

NextNRG, Inc.

About NextNRG, Inc.

NextNRG, Inc. (NextNRG) is Powering What’s Next by deploying its AI-driven Smart Controller, a proprietary AI technology that continuously optimizes how energy is generated, stored, and consumed. The Company deploys the controller within microgrids at commercial, healthcare, municipal, industrial and federal sites, and at a utility scale through the Next Utility Operating System®.

NextNRG also sells EV chargers, is advancing wireless in-motion charging, and operates one of the nation’s largest on-demand mobile fueling fleets through EzFill.

To learn more, visit www.nextnrg.com.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement describing NextNRG’s goals, expectations, financial or other projections, intentions, or beliefs is a forward-looking statement and should be considered an at-risk statement. Words such as “expect,” “intends,” “will,” and similar expressions are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including, but not limited to, those related to NextNRG’s business and macroeconomic and geopolitical events. These and other risks are described in NextNRG’s filings with the Securities and Exchange Commission from time to time. NextNRG’s forward-looking statements involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such statements. Although NextNRG’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by NextNRG. Except as required by law, NextNRG undertakes no obligation to update any forward-looking statements for any reason. As a result, you are cautioned not to rely on these forward-looking statements.

Investor Relations ContactNextNRG, Inc.
Sharon Cohen
SCohen@nextnrg.com

MONTERREY, Mexico, Sept. 14, 2026 (GLOBE NEWSWIRE) — Fomento Económico Mexicano, S.A.B. de C.V. (“FEMSA” or the “Company”) (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) today announced that, as part of its ongoing efforts and consistent with its capital allocation framework and commitment to enhance capital returns to shareholders, it has entered into a new derivative instrument known as an accelerated share repurchase (“ASR”) agreement with a financial institution in the United States of America to repurchase Company’s shares through the acquisition of American Depositary Shares (“ADS”). Under the terms of the ASR agreement, FEMSA has agreed to repurchase from such financial institution an aggregate amount of up to USD $280 million of its ADS¹, subject to market conditions and delivered at maturity.

The final number of ADSs repurchased and delivered under the ASR agreement will be based on the daily volume-weighted average ADS price during the agreement term, less a discount, and subject to the agreement’s terms and conditions. Final settlement is expected to occur before year-end 2026.

About FEMSA
FEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in two core sectors, retail and beverages. In retail, FEMSA is present through four divisions: i) OXXO Mexico, operating the largest small-format store chain in Mexico; ii) Americas & Mobility, which includes its OXXO convenience store operations across Latin America and the United States, as well as its gas station business in Mexico and the United States; iii) Europe, operating convenience and foodvenience formats in five European countries; and iv) FEMSA Health, which includes drugstores and related activities in four Latin American countries. In Mexico, OXXO’s operations are enhanced by, and comprise a customer-focused ecosystem with Spin, a digital platform that leverages the OXXO store network to provide Mexican consumers with access to digital financial services, including Spin by OXXO and Spin Premia, among other initiatives. In the beverage sector, FEMSA participates through Coca-Cola FEMSA, the largest franchise bottler of Coca-Cola products in the world by volume. Across its business units, FEMSA has more than 369,000 employees in 18 countries. FEMSA is a member of the Dow Jones Best-in-Class World Index & Dow Jones Best-in-Class MILA Pacific Alliance Index, both from S&P Global; FTSE4Good Emerging Index; MSCI EM Latin America ESG Leaders Index; S&P/BMV Total México ESG, among other indexes.

^{__________________________________________________
1} ADS underlying units consist of 10 of FEMSA’s BD Units, each representing one Series B Share, two Series D-B Shares and two Series D-L Shares, without par value.

CONTACT: Investor Contact
(52) 818-328-6000
investor@femsa.com
femsa.gcs-web.com

Media Contact
(52) 555-249-6843
comunicacion@femsa.com
femsa.com

Artea Bankas AB, company code 112025254, address of the head office Tilžės str. 149, Šiauliai, Lithuania.

Artea bankas AB has received the notification of the persons, closely associated with the manager, in securities issued by the bank (attached). 

Additional information: 
Arnas Šukys 
Head of Investor Relations
arnas.sukys@artea.lt, +370 610 44447

Attachment

• ROE1L_Invalda INVL_notification_end of pledge

Highlights 3nm Production, 2nm Design, 3DIC Capabilities and Multi-Die Advanced Packaging

SAN JOSE, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) — Alchip Technologies, the high-performance ASIC leader, will showcase its leading-edge process technology and advanced packaging achievements in Booth 1705 at AI Infra Summit 2026.

The event runs from September 15 through September 17 at the Santa Clara Convention Center in Santa Clara, California.

At the exhibit, Alchip will discuss its 3nm designs in production and 2nm designs currently in development. The company will also showcase its complete 2nm design platform, 3nm I/O chiplet support, and functional optical interconnect capabilities. Today, 90% of the company’s designs use process technologies below 7nm.

Alchip will also focus on its advanced packaging capabilities, highlighting its 3DIC ecosystem readiness and experience working with multiple TSMC CoWoS^® technologies. These capabilities include TSMC 2nm CoWoS^® designs, TSMC CoWoS^®-S and TSMC CoWoS^®-R designs in production, TSMC CoWoS^®-L and TSMC SoIC^®-X designs in development. The company will highlight its proven 3DIC capabilities, co-packaged optics technology and high-performance die-to-die IP.

Alchip has completed more than 650 successful tape-outs since its founding in 2003 and currently completes 10 to 20 new tape-outs annually. Its track record covers more than 60 FinFET designs and more than 20 CoWoS designs, with a focus on AI and high-performance computing, networking and automotive applications.

About Alchip

Alchip Technologies Ltd., founded in 2003 and headquartered in Taipei, Taiwan, is a leading global High-Performance Computing and AI infrastructure ASIC provider of IC and packaging design, and production services for companies developing complex and high-volume ASICs and SoCs.  Alchip provides faster time-to-market and cost-effective solutions for SoC design at mainstream and advanced process technology. Alchip has built its reputation as a high-performance ASIC leader through its advanced 2.5D/3D CoWoS packaging, chiplet design, and manufacturing management. Customers include global leaders in artificial intelligence, high-performance computing, supercomputing, mobile communications, entertainment device, networking equipment, and other electronic product categories. Alchip is listed on the Taiwan Stock Exchange (TWSE: 3661).

Note: CoWoS®, CoWoS^®-S and CoWoS^®-R, CoWoS^®-L, SoIC®, and related advanced packaging terminology are trademarks or registered trademarks of Taiwan Semiconductor Manufacturing Company Limited (TSMC). They are used here solely to describe TSMC technologies incorporated within Alchip’s design and development activities.

For more information, please visit our website: http://www.alchip.com

CONTACT: Charles Byers
Alchip Technologies
+ (408)-310-9244
chuck_byers@alchip.com

ANDOVER, Mass., Sept. 14, 2026 (GLOBE NEWSWIRE) — MKS Inc. (NASDAQ: MKSI), a global provider of enabling technologies that transform our world, today released its 2026 Environmental, Social, Governance (“ESG”) Report, outlining how MKS continues to integrate sustainability into its strategy, operations, and decision-making to support long-term value creation.

“At MKS, operational excellence, risk management, and responsible growth, together with an unwavering commitment to innovation, integrity, and trust, are foundational to our sustainability efforts,” said John T.C. Lee, President and CEO. “This report details MKS’ continued progress in improving efficiency, reducing resource use, and supporting safer, more reliable operations, while making targeted investments that strengthen our global footprint and bring our expertise and resources closer to our customers.”

The 2026 ESG Report also highlights several of our key ESG achievements since the beginning of 2025, including:

• Science Based Targets initiative (SBTi) approval of MKS’ near-term Scope 1, 2, and 3 greenhouse gas (GHG) emissions reduction targets.
• Generation of approximately 1,500 MWh of electricity from a new rooftop solar installation at MKS’ Guangzhou, China equipment factory, avoiding nearly 900 tCO2e emissions annually.
• Achievement of a record 91% participation rate in MKS’ fifth annual Global Employee Engagement Survey.
• Continued external ESG recognition, including a low ESG risk rating from Sustainalytics and recognition as one of the Best Companies to Work For by U.S. News & World Report, one of America’s Best Midsized Companies by Time and Statista, Inc. and one of America’s Most Responsible Companies by Newsweek and Statista, Inc.

The report is available to view here and includes relevant disclosures related to The Sustainability Accounting Standards Board (SASB) and The Task Force on Climate-related Financial Disclosures (TCFD) standards.

About MKS Inc.
MKS Inc. (NASDAQ: MKSI) enables technologies that transform our world. We deliver foundational technology solutions to leading edge semiconductor manufacturing, electronics and packaging, and specialty industrial applications. We apply our broad science and engineering capabilities to create instruments, subsystems, systems, process control solutions and specialty chemicals technology that improve process performance, optimize productivity and enable unique innovations for many of the world’s leading technology and industrial companies. Our solutions are critical to addressing the challenges of miniaturization and complexity in advanced device manufacturing by enabling increased power, speed, feature enhancement, and optimized connectivity. Our solutions are also critical to addressing ever-increasing performance requirements across a wide array of specialty industrial applications. Additional information can be found at www.mks.com.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 regarding MKS’ environmental goals. Any statements that are not statements of historical fact should be considered to be forward-looking statements. Actual events or results may differ materially from those in the forward-looking statements set forth herein as a result of various important factors, including the factors described in MKS’ Annual Report on Form 10-K for the year ended December 31, 2025, and any subsequent Quarterly Reports on Form 10-Q, as filed with the U.S. Securities and Exchange Commission. MKS is under no obligation to, and expressly disclaims any obligation to, update or alter these forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.

Contacts:

Bill Casey
Vice President, Marketing
Telephone: +1 (630) 995-6384
Email: press@mksinst.com

Kerry Kelly, Partner
Kekst CNC
Email: kerry.kelly@kekstcnc.com